Trending...
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Mortgage Rates And Demand Are Stuck In A Holding Pattern
- This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
WILLOWBROOK, Ill., May 3, 2021 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care. The Company is marketing Centhaquine Citrate, with the brand name Lyfaquin® to health care professionals in India.
Pharmazz is pleased to announce the peer-reviewed publication of the manuscript titled "Centhaquine Restores Renal Blood Flow and Protects Tissue Damage After Hemorrhagic Shock and Renal Ischemia." The manuscript is published in Frontier in Pharmacology and is available https://doi.org/10.3389/fphar.2021.616253. Lyfaquin® increased renal blood flow, augmented hypoxia response, decreased tissue damage, and apoptosis following hemorrhagic shock-induced acute kidney injury (AKI) in the rat.
AKI has significantly increased in the past couple of decades. Its incidence can reach up to 50% in critically ill patients. The etiology of AKI may be multifactorial and is substantially associated with increased morbidity and mortality. AKI as an in-hospital complication of sepsis, heart conditions, and surgery is increasingly recognized. It commonly occurs in patients with septic shock, hemorrhagic shock, COVID-19. About one-third of patients hospitalized with COVID-19 develop AKI. Besides, AKI occurs from some antibiotics, contrast media, and poisons.
More on illi News
The study results indicate that resuscitation with Lyfaquin® helps protect kidney tissues by increasing tissue blood perfusion (p=0.003), and hypoxia-inducible factors mediated anti-apoptotic and survival responses. Lyfaquin® could enhance blood flow in kidneys after acute injury and had an anti-apoptotic role mediated via hypoxia-responsive factors activation, which would promote angiogenesis and metabolic adaptation in injured tissues for their survival and function. Histopathological analysis showed that treatment with Lyfaquin® decreased the pathological damage score (p=0.078) in hemorrhagic shock-induced AKI in the rat. Early kidney damage marker, neutrophil gelatinase-associated lipocalin (NGAL) was significantly (p=0.016) reduced in the Lyfaquin® group than the control group.
Lyfaquin® is a frontline therapy used in conjunction with the standard of care and is well-positioned to address critical unmet needs in hypovolemic shock. Lyfaquin® is well tolerated, with no serious adverse events attributed to Lyfaquin®. Pharmazz plans to advance this indication of AKI towards clinical studies and work with regulatory agencies to make Lyfaquin® available to patients with AKI.
About Pharmazz, Inc.
Pharmazz, Inc. is a privately held company engaged in developing novel products in critical care medicine. Additional information may be found on the Company's website, www.pharmazz.com.
More on illi News
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations. They involve many risks and uncertainties, including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering, or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law, Pharmazz, Inc. does not intend to update any forward-looking statements to conform these statements to actual results.
Contact
Pharmazz, Inc.
Shruti Gulati
630-780-6087
[email protected]
SOURCE Pharmazz, Inc.
Related Links
http://www.pharmazz.com
Pharmazz is pleased to announce the peer-reviewed publication of the manuscript titled "Centhaquine Restores Renal Blood Flow and Protects Tissue Damage After Hemorrhagic Shock and Renal Ischemia." The manuscript is published in Frontier in Pharmacology and is available https://doi.org/10.3389/fphar.2021.616253. Lyfaquin® increased renal blood flow, augmented hypoxia response, decreased tissue damage, and apoptosis following hemorrhagic shock-induced acute kidney injury (AKI) in the rat.
AKI has significantly increased in the past couple of decades. Its incidence can reach up to 50% in critically ill patients. The etiology of AKI may be multifactorial and is substantially associated with increased morbidity and mortality. AKI as an in-hospital complication of sepsis, heart conditions, and surgery is increasingly recognized. It commonly occurs in patients with septic shock, hemorrhagic shock, COVID-19. About one-third of patients hospitalized with COVID-19 develop AKI. Besides, AKI occurs from some antibiotics, contrast media, and poisons.
More on illi News
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- New Dad Battles Leukemia and Wins!
- Kefir Comes to NASCAR as Lifeway Foods Races into Hometown Weekend with Driver Josh Bilicki at The Loop 110
- Recession-Proof Startups: What Business Plans Investors Are Actually Funding in 2025
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
The study results indicate that resuscitation with Lyfaquin® helps protect kidney tissues by increasing tissue blood perfusion (p=0.003), and hypoxia-inducible factors mediated anti-apoptotic and survival responses. Lyfaquin® could enhance blood flow in kidneys after acute injury and had an anti-apoptotic role mediated via hypoxia-responsive factors activation, which would promote angiogenesis and metabolic adaptation in injured tissues for their survival and function. Histopathological analysis showed that treatment with Lyfaquin® decreased the pathological damage score (p=0.078) in hemorrhagic shock-induced AKI in the rat. Early kidney damage marker, neutrophil gelatinase-associated lipocalin (NGAL) was significantly (p=0.016) reduced in the Lyfaquin® group than the control group.
Lyfaquin® is a frontline therapy used in conjunction with the standard of care and is well-positioned to address critical unmet needs in hypovolemic shock. Lyfaquin® is well tolerated, with no serious adverse events attributed to Lyfaquin®. Pharmazz plans to advance this indication of AKI towards clinical studies and work with regulatory agencies to make Lyfaquin® available to patients with AKI.
About Pharmazz, Inc.
Pharmazz, Inc. is a privately held company engaged in developing novel products in critical care medicine. Additional information may be found on the Company's website, www.pharmazz.com.
More on illi News
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- City of Chicago Releases Annual Comprehensive Financial Report for Fiscal Year 2024
- Indies United is pleased to present our July 2025 book releases
- Endurance Warranty Earns 2025 Buyer's Choice Awards from ConsumerAffairs Through Verified Customer Reviews
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations. They involve many risks and uncertainties, including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering, or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law, Pharmazz, Inc. does not intend to update any forward-looking statements to conform these statements to actual results.
Contact
Pharmazz, Inc.
Shruti Gulati
630-780-6087
[email protected]
SOURCE Pharmazz, Inc.
Related Links
http://www.pharmazz.com
Filed Under: Business
0 Comments
Latest on illi News
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- Mt. Carmel's Claude Mpouma to Announce College Commitment — Media Invited
- Bennett Awards Crafts Custom Trophies for Inaugural OMTEC Awards at 2025 Orthopedic Expo
- Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
- Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
- Winners Announced for Asia Pacific Business Awards 2024-2025
- Hamvay-Lang and Lampone.hu Join Forces with AIMarketingugynokseg.hu to Elevate Hungarian Lifestyle Brands on the Global Stage
- Google AI Quietly Corrects the Record on Republic of Aquitaine's Legal Sovereignty
- The Lashe Rapid Dry Adhesive & Fan Lash Extensions Featured in eWellness Magazine's Lash Story
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence
- Chicago: Mayor Brandon Johnson Announces 2026 Budget Engagement Roundtables
- Make Innovation Matter: Support H.R.1's R&D Expensing Relief for American Small Businesses
- Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI)
- Byrd Davis Alden & Henrichson Launches Independence Day Safe Ride Initiative with 500 Free Uber Credits
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Universal Destinations & Experiences Plans Second Universal Horror Unleashed in Chicago
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- Big Green Egg and Ace Hardware Launch "Egg Your Neighbor" Contest to Celebrate Neighborhood Heroes
- Pi9 Becomes a Microsoft Training Services Partner